Clinical evaluation of Shufeng Jiedu Capsules combined with umifenovir (Arbidol) in the treatment of common-type COVID-19: a retrospective study-Reference-Cited by-同舟云学术

Clinical evaluation of Shufeng Jiedu Capsules combined with umifenovir (Arbidol) in the treatment of common-type COVID-19: a retrospective study

Published:2020-09-17 Issue:2 Volume:15 Page:257-265
ISSN:1747-6348
Container-title:Expert Review of Respiratory Medicine
language:en
Short-container-title:Expert Review of Respiratory Medicine

Author:

Chen Jing¹²,Lin Shaowu³,Niu Conway⁴,Xiao Qi²

Affiliation:

1. Department of Child Health, Women and Children’s Hospital, School of Medicine, Xiamen University, Xiamen, China

2. Department of Nephrology, Xiamen Haicang Hospital, Xiamen, China

3. School of Public Health, Xiamen University, Xiamen, China

4. Department of Medical Paediatrics, Royal Aberdeen Children’s Hospital, Aberdeen, Scotland, United Kingdom

Funder

Natural Science Foundation of Fujian

Fujian Young/Middle-aged Talent Cultivation

Xiamen Science and Technology Commission

Publisher

Informa UK Limited

Subject

Public Health, Environmental and Occupational Health,Pulmonary and Respiratory Medicine,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/17476348.2020.1822741

Reference26 articles.

1. A Novel Coronavirus from Patients with Pneumonia in China, 2019

2. Notification of COVID-19 infection. National Health Commission of the People’s Republic of China. [cited 2020 Aug 28]. http://www.nhc.gov.cn/xcs/yqtb/202002/17a03704a99646ffad6807bc806f37a4.shtml (in Chinese).

3. World Health Organization. Coronavirus disease 2019 (COVID-19) situation report-146[EB/OL]. [cited 2020 Aug 28]. https://www.who.int/docs/default-source/coronaviruse/situationreports/20200321-sitrep-61-covid-19.pdf?sfvrsn=f201f85c_2

4. World Health Organization. Director-general’s remarks at the media briefing on 2019-nCoV on 11 February 2020. [cited 2020 Feb 12]. https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020

5. A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of seven oral traditional Chinese medicines against mild or moderate COVID-19: An updated systematic review and network meta-analysis;Heliyon;2024-08

2. Anti-SARS-CoV-2 activity of steroids from traditional Chinese medicines in vitro;2024-06-13

3. Shufeng Jiedu capsule alleviates influenza A (H1N1) virus induced acute lung injury by regulating the lung inflammatory microenvironment;Heliyon;2024-06

4. Chinese herbal medicine Shufeng Jiedu capsule for mild to moderate COVID-19: a multicenter, randomized, double-blind, placebo-controlled phase II trial;Frontiers in Pharmacology;2024-05-27

5. An Overview of SARS-CoV-2 Potential Targets, Inhibitors, and Computational Insights to Enrich the Promising Treatment Strategies;Current Microbiology;2024-05-11